Compare Prudential Financial Inc (PRU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Prudential Financial Inc trades at $111.65 (market cap $39.17B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× Prudential Financial Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PRU | VRTX | |
|---|---|---|
Market Cap | $39.17B | $127.55B |
Volume | 1,436,917 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $125.13 | $557.96 |
52-Week Low | $92.00 | $407.37 |
Typical Hold Time | 145 Days | 120 Days |
Enterprise Value | $67.95B | $121.68B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $112.36, down 1.04% with bearish technical signals despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent strategic moves include exiting emerging markets with Alexforbes sale and rebranding to Prudential Wealth Advisors, reflecting focus on core operations.
While valuation appears compelling and higher interest rates benefit investment income, analyst sentiment remains cautious with 67.57% hold ratings. The stock faces execution risks from strategic restructuring and competitive pressures in insurance markets. Current price near consensus target of $105.67 suggests limited near-term upside despite fundamental strength.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
